Capsule switching and capsule replacement in vaccine-preventable bacterial diseases

Lancet Infectious Diseases

Volumn 7, Issue 9, 2007, Pages 569-570

  Tsang, Raymond ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE;

BACTERIAL CELL WALL; BACTERIAL INFECTION; BACTERIUM ISOLATE; GENETIC VARIABILITY; HAEMOPHILUS INFLUENZAE; HUMAN; LETTER; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEROTYPE; STREPTOCOCCUS PNEUMONIAE;

BACTERIAL INFECTIONS; BACTERIAL VACCINES; CAPSULES; HUMANS; MEDICAL ERRORS;

EID: 34547948567     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(07)70191-3     Document Type: Letter

References (14)

1. Trotter C., Ramsay M., Gray S., Fox A., and Kaczmarski E. No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales. Lancet Infect Dis 6 (2006) 616-617
2. Musher D. Pneumococcal vaccine-direct and indirect ("herd") effects. N Engl J Med 354 (2006) 1522-1524
3. Long S. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine. Clin Infect Dis 41 (2005) 30-34
4. Byington C., Samore M., Stoddard G., et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the Intermountain West: emergence of nonvaccine serogroups. Clin Infect Dis 41 (2005) 21-29
5. Bajanca P., and Canica M. Emergence of nonencapsulated and encapsulated non-b-type invasive Haemophilus influenzae isolates in Portugal (1989-2001). J Clin Microbiol 42 (2004) 807-811
6. Ribeiro G., Reis J., Cordeiro S., et al. Prevention of Haemophilus influenzae type b (Hib) meningitidis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis 187 (2003) 109-116
7. Alcala B., Arreaza L., Salcedo C., Uria M., De La Fuente L., and Vazquez J. Capsule switching among C:2b:P1.2,5 meningococcal epidemic strains after mass immunization campaign, Spain. Emerg Infect Dis 8 (2002) 1512-1514
8. Lancellotti M., Guiyoule A., Ruckly C., Hong E., Alonso M., and Taha M. Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect 8 (2006) 191-196
9. Tyler S., and Tsang R. Genetic analysis of Canadian isolates of C:2a:P1.2,5 and B:2a:P1.2,5 Neisseria meningitidis strains belonging to the hypervirulent clone of ET-15. Can J Microbiol 50 (2004) 433-443
10. Law D., Lorange M., Ringuette L., et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P.19 (B:17:P1.19). J Clin Microbiol 44 (2006) 2743-2749
11. Tsang R., Tsai C., Zhu P., et al. Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada. J Clin Microbiol 42 (2004) 1460-1465
12. Diggle M., and Clarke S. Increased genetic diversity of Neisseria meningitidis isolates after the introduction of meningococcal serogroup C polysaccharide conjugate vaccines. J Clin Microbiol 43 (2005) 4649-4653
13. Gray S., Trotter C., Ramsay M., et al. Epidemiology of meningococcal disease in England and Wales. 1993/94 to 2003/04: contribution and experience of the meningococcal reference unit. J Med Microbiol 55 (2006) 887-896
14. Harrison L., Jolley K., Shutt K., et al. Antigenic shift and increased incidence of meningococcal disease. J Infect Dis 193 (2006) 1266-1274